Five Key Investment Highlights about Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF)
- Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) has developed a breakthrough, science-backed product that is the first 100% plant-based, non-dairy, non-soy infant formula.
- Else Nutrition Holdings (TSX.V:BABY) (OTCQB:BABYF) has an incredibly strong IP portfolio, valid through 2034, with patents granted in more than 19 countries.
- Strong Pipeline for 2020, including Else Formula for toddlers (ages 12 months to 36 months) as well as Else Kids complementary nutritional drink (ages 3y-12y), is going to be launched in the second quarter of 2020. On top of that, the company has many other products in development.
- Through the sale of its vegan baby snacks as well as its bottles and accessories in Israel, Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) is already generating revenue—USD$800,000 in 2018.
- The worldwide industry for infant formula will be worth USD$90 Billion by 2025.
Technical Analysis
In recent years, it has become abundantly clear that plant-based solutions will revolutionize the food industry. While a great number of corporations are engaged in producing plant-based meat, companies involved in producing plant-based nutrition for babies and toddlers are hardly known, mainly due to the very unique expertise required in that field.
While less than a handful of companies have entered this particular space, from the point of view of investors, Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) is certainly the most promising one.
The company has developed its own formula for the infant nutrition industry—and considering that the market is currently worth $70 billion, it’s worth taking a closer look at Else.
100% Plant-Based baby food formula
The company’s baby food formula is a one of a kind product. This is because it’s 100% plant-based, made without soy, without dairy, and without GMOs. It’s also entirely devoid of hormones, antibiotics, and chemicals which makes it a clean label, clean process product, and the right solution for parents in an increasingly health-conscious world.
According to market research firms, the infant formula industry could be worth as much a $90 billion by 2025. The opportunity for Else Nutrition is huge, and it stems from the fact that both milk and soy cause high intolerance levels in babies. Many parents wish to avoid these two ingredients, and have no other alternative.
Research suggests that a substantial percentage of babies who are allergic to cow’s milk are also allergic to soy. This suggests that almost all of Else Nutrition Holdings Inc.’s (TSX.V:BABY) (OTCQB:BABYF) direct competitors are out of the market right away.
On top of that, research suggests that 33% of Americans are flexitarians and wish to minimize their family’s animal protein consumption. Research also suggests 1 out of every 12 American families are going to raise their children as vegans. This opens up another massive opportunity for the company, as Else Nutrition is delivering the infant formula those families will rely on.
Potential investors have to be optimistic about how Else Nutrition has managed to fill this glaring gap in the market.
The infant baby formula industry has not seen considerable innovation for more than a century, as the entire baby formula space is dominated by cow’s milk. However, the emergence of a company like Else Nutrition is set to deliver the sort of disruption that is inevitable after such a long time.
Impressive Products Launch Pipeline For 2020
The Else Baby Formula for Toddlers (ages 12 months to 36 months) will be launched in the second quarter of 2020, and it is important to note that the company has many additional products in the pipeline, including an infant formula (0-12 months).
After that, Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) has stated it intends to become the first and almost the only viable alternative to the entire baby formula industry, which is based on cow’s milk and soy.
The company’s plans are ambitious, which is why it’s important to note that Else Nutrition does not lack the necessary financial muscle. It recently raised CA$7.5 million from Canaccord Genuity Inc and is looking to grow quickly. The company’s founders have experience working in such big-ticket firms like Nestle, and Abbott, which makes it easier for Else Nutrition to navigate the world of big business.
Moreover, Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) is already generating revenues by selling its products like bottles, accessories, and vegan baby snacks in Israel. In 2018, it generated US$800,000 in revenue from those sales.
Once it launches its products in the United States, the company’s growth could go through the roof. The company will initially sell its products online via Amazon, and will partner with specialty retail chains, later expanding into mass market retail chains. On top of that, the company’s formula is endorsed by leading experts and meets the WHO Codex guidelines as well as international regulations for infant nutrition.
Proprietary, Protected Advanced Products
Globally-patented, the Else formula composition (as opposed to technology or process-based) is closely guarded.
Finally, Else Nutrition (TSX.V:BABY) (OTCQB:BABYF) has a very strong IP portfolio, valid through 2034, with patents already granted in more than 19 countries. This includes: the USA, Australia, Eurasia (Russia, Belarus + 10 others), Ukraine, Japan, South Africa, and Israel, Patents are also pending in more than 46 countries.
For a full research report, please visit this link.
Featured image: Canva
